ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed 09 December 8:00AM
Realtime Data

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
42.20
Bid
41.80
Offer
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
dbergh dbergh 4 minutes ago
Well you obviously don't care about those who suffer emotional torment with their gender identity.
You clearly would have them suffer rather than be treated. That's just the fact around your attitude re them.
And it sucks that you are totally lack all empathy for their situations.
wadegarret wadegarret 5 minutes ago
SMCI maybe goes to $60+ before BDO

even gives an opinion ? The stock is highly risky at this point IMO. I mean anyone who would risk playing a stock that just went from $125 to $17, and has now almost tripled without being 100% sure that they're not overstating revenues is gamblin
SMCI
dinogreeves dinogreeves 5 minutes ago
I believe we have one great stock. This should really well.
QBTS
trainer2 trainer2 5 minutes ago
Yes, an example is if you tell a human to never run a stop sign sometimes they will. The Tesla will NEVER run the stop sign. Same goes with red lights.
This prevents lots of accidents.
TSLA
Lime Time Lime Time 6 minutes ago
I remember this one from back in the day. On watch for some volume. Huge OTC shaping up
NBRI
WinstonCup WinstonCup 6 minutes ago
Btw, I know what I am doing. Wasting my time going back and forth with someone obtuse. Ignore now.
WDLF
wadirum1 wadirum1 6 minutes ago
For folks who are new to this board, there are a TON of posts about "CEO dress up", by which the bashers are referring to the CEO's minor acting gigs. Why people feel the need to post about that -- sometimes multiple times a day -- is something we'll never know. The board reads a lot better if you
HHSE
stockinspector stockinspector 7 minutes ago
Yep, too bad, but I am ready.
WDLF
Lime Time Lime Time 7 minutes ago
This is way pre-HMBL pre-TSNP, all a shell. GS can pull off a huge win here soon, it's a good market again. Let's see what happens this week. I wasn't expecting volumes until 2025, hence end of year tax loss selling, but this is doing the opposite.
HMBL
observer21 observer21 7 minutes ago
I am excited to see what becomes of the CEO's presentation at Benchmark this Wednesday. Benchmark is no slouch on Wall Street. If you go to "The Benchmark Company" website and scroll all the way down and click on the "Recent Transactions" link you get an idea of how immersed in finance these people
AERG
bobby1151 bobby1151 9 minutes ago
Good work!!
BIEL
WinstonCup WinstonCup 9 minutes ago
I'm impressed, too bad Ken and company has been in failure mode past 3 years.
WDLF
WeTheMarket WeTheMarket 9 minutes ago
EVgo and GM Surpass 2,000 Public Fast Charging Stalls in the U.S.
December 04 2024
https://ih.advfn.com/stock-market/NASDAQ/evgo-EVGO/stock-news/95035554/evgo-and-gm-surpass-2-000-public-fast-charging-sta
EVGO
Juststoppingby Juststoppingby 12 minutes ago
Is Coretec’s Endurion battery technology about to be commercialized/licensed? I say this because of their press release and the filing on Dart S. Korea. Some things stood out to me.

Quotes:
“and preparing for mass production. In addition, the company is about to be listed on th
CRTG
wakeupdummy wakeupdummy 14 minutes ago
yes,and people will be more inclined to invest speculatively
this is riding off HMBL now but it'll carry it's self later in 25. ;-)
HMBL
Hosai Hosai 14 minutes ago
"The critical question for CM and CHMP is how to interpret the 75% OLE dropout rate: does it undermine the validity of the OLE results,"

You can't deduct the OLE dropout from compassionate use numbers so simply. Prob on average around 40-60% will continue from an OLE to taking a drug
AVXL
stockinspector stockinspector 16 minutes ago
How about that jump of 989% the week of 12/07/20 did you get any of that?
of course the huge breakout in February of 2021
WDLF went up 138% on the week of 8/2/21
Another bump of 259% the week of 8/16/21
207% in week of 1/18/22
3 more bumps of 120% - 100% - 64% b
WDLF
Fdc4 Fdc4 16 minutes ago
It is amazing the scare tactics some individuals uses in order to take cheapies away from others. I don’t care, if the ticker was created 12 months ago, I don’t care if the company is associated with lawsuits from the past… Eyes on the ball, many of us were frozen with HMBL, doomed And YBRA has
ENZC HMBL OTCM
New money98 New money98 17 minutes ago
Lollll....Ok so when I post what went on before the Ccaa Liquidation PROCESS, proof of R exhibits, AGGREGATE purchases, C.a., N.d.a, what's under seal still to this day, proof of a letter for investment in Sarnia seperate from the letter for investment in bioamber inc. and much more. All I ask is t
LA4321 LA4321 18 minutes ago
YO GAALSWYK----------heres what you COULD do tomorrow--------a "PR"----------" " it is NOT part of our corporate direction to pursue a RS ""--------------and ya dont need to hire a boiler room to do it !!!!!!!!!!!
DUTV
Atown62 Atown62 20 minutes ago
-2500 odds 

The ceo knows nothing else

He loves to lie and deceive 

But most of all LOVES to DRESS UP 👗 
HHSE

Your Recent History

Delayed Upgrade Clock